Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,020 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Low-dose dasatinib in older patients with chronic myeloid leukaemia in chronic phase (DAVLEC): a single-arm, multicentre, phase 2 trial.
Murai K, Ureshino H, Kumagai T, Tanaka H, Nishiwaki K, Wakita S, Inokuchi K, Fukushima T, Yoshida C, Uoshima N, Kiguchi T, Mita M, Aoki J, Kimura S, Karimata K, Usuki K, Shimono J, Chinen Y, Kuroda J, Matsuda Y, Nakao K, Ono T, Fujimaki K, Shibayama H, Mizumoto C, Takeoka T, Io K, Kondo T, Miura M, Minami Y, Ikezoe T, Imagawa J, Takamori A, Kawaguchi A, Sakamoto J, Kimura S. Murai K, et al. Among authors: kawaguchi a. Lancet Haematol. 2021 Dec;8(12):e902-e911. doi: 10.1016/S2352-3026(21)00333-1. Lancet Haematol. 2021. PMID: 34826413 Clinical Trial.
A new highly sensitive real-time quantitative-PCR method for detection of BCR-ABL1 to monitor minimal residual disease in chronic myeloid leukemia after discontinuation of imatinib.
Kitamura H, Tabe Y, Ai T, Tsuchiya K, Yuri M, Misawa S, Horii T, Kawaguchi A, Ohsaka A, Kimura S. Kitamura H, et al. Among authors: kawaguchi a. PLoS One. 2019 Mar 5;14(3):e0207170. doi: 10.1371/journal.pone.0207170. eCollection 2019. PLoS One. 2019. PMID: 30835732 Free PMC article.
Treatment-free remission after first-line dasatinib discontinuation in patients with chronic myeloid leukaemia (first-line DADI trial): a single-arm, multicentre, phase 2 trial.
Kimura S, Imagawa J, Murai K, Hino M, Kitawaki T, Okada M, Tanaka H, Shindo M, Kumagai T, Ikezoe T, Uoshima N, Sato T, Watanabe R, Kowata S, Hayakawa M, Hosoki T, Ikeda K, Kobayashi T, Kakinoki Y, Nishimoto T, Takezako N, Shibayama H, Takaori-Kondo A, Nakamae H, Kawaguchi A, Ureshino H, Sakamoto J, Ishida Y; DADI Trial Group. Kimura S, et al. Among authors: kawaguchi a. Lancet Haematol. 2020 Mar;7(3):e218-e225. doi: 10.1016/S2352-3026(19)30235-2. Epub 2020 Jan 21. Lancet Haematol. 2020. PMID: 31978329 Clinical Trial.
Silylation of Deoxynucleotide Analog Yields an Orally Available Drug with Antileukemia Effects.
Ureshino H, Kurahashi Y, Watanabe T, Yamashita S, Kamachi K, Yamamoto Y, Fukuda-Kurahashi Y, Yoshida-Sakai N, Hattori N, Hayashi Y, Kawaguchi A, Tohyama K, Okada S, Harada H, Ushijima T, Kimura S. Ureshino H, et al. Among authors: kawaguchi a. Mol Cancer Ther. 2021 Aug;20(8):1412-1421. doi: 10.1158/1535-7163.MCT-20-1125. Epub 2021 May 27. Mol Cancer Ther. 2021. PMID: 34045225 Free PMC article.
Feasibility of the imatinib stop study in the Japanese clinical setting: delightedly overcome CML expert stop TKI trial (DOMEST Trial).
Fujisawa S, Ueda Y, Usuki K, Kobayashi H, Kondo E, Doki N, Nakao T, Kanda Y, Kosugi N, Kosugi H, Kumagai T, Harada H, Shikami M, Maeda Y, Sakura T, Inokuchi K, Saito A, Nawa Y, Ogasawara M, Nishida J, Kondo T, Yoshida C, Kuroda H, Tabe Y, Maeda Y, Imajo K, Kojima K, Morita S, Komukai S, Kawaguchi A, Sakamoto J, Kimura S. Fujisawa S, et al. Among authors: kawaguchi a. Int J Clin Oncol. 2019 Apr;24(4):445-453. doi: 10.1007/s10147-018-1368-2. Epub 2018 Nov 12. Int J Clin Oncol. 2019. PMID: 30421023 Free PMC article. Clinical Trial.
Clinical impact of the CONUT score in patients with multiple myeloma.
Okamoto S, Ureshino H, Kidoguchi K, Kusaba K, Kizuka-Sano H, Sano H, Nishioka A, Yamaguchi K, Kamachi K, Itamura H, Yoshimura M, Yokoo M, Shindo T, Kubota Y, Ando T, Kojima K, Kawaguchi A, Sueoka E, Kimura S. Okamoto S, et al. Among authors: kawaguchi a. Ann Hematol. 2020 Jan;99(1):113-119. doi: 10.1007/s00277-019-03844-2. Epub 2019 Nov 25. Ann Hematol. 2020. PMID: 31768678 Clinical Trial.
Targeting aberrant DNA hypermethylation as a driver of ATL leukemogenesis by using the new oral demethylating agent OR-2100.
Watanabe T, Yamashita S, Ureshino H, Kamachi K, Kurahashi Y, Fukuda-Kurahashi Y, Yoshida N, Hattori N, Nakamura H, Sato A, Kawaguchi A, Sueoka-Aragane N, Kojima K, Okada S, Ushijima T, Kimura S, Sueoka E. Watanabe T, et al. Among authors: kawaguchi a. Blood. 2020 Aug 13;136(7):871-884. doi: 10.1182/blood.2019003084. Blood. 2020. PMID: 32391874 Free article.
Origin of circulating free DNA in patients with lung cancer.
Abe T, Nakashima C, Sato A, Harada Y, Sueoka E, Kimura S, Kawaguchi A, Sueoka-Aragane N. Abe T, et al. Among authors: kawaguchi a. PLoS One. 2020 Jul 7;15(7):e0235611. doi: 10.1371/journal.pone.0235611. eCollection 2020. PLoS One. 2020. PMID: 32634139 Free PMC article.
1,020 results